Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.11.111PMID 15738531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

  2004cited by this paper
• Adaptive Two‐Stage Designs for Single‐Arm Phase IIA Cancer Clinical Trials

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma

  2001cited by this paper
• Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.

  2001cited by this paper
• Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.

  2001cited by this paper
• Targeting apoptosis in prostate cancer.

  2001cited by this paper
• Clinical highlights from the National Cancer Data Base, 2000

  2000cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• The promoter of the prostate-specific antigen gene contains a functional androgen responsive element.

  1991cited by this paper

• Aspects of Chemotherapy in Prostate Cancer

  2021cites this paper
• Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?

  2021cites this paper
• Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial

  2019cites this paper
• Chemotherapy in the Treatment of Prostate Cancer — The Past, the Present, and the Future

  2014cites this paper
• A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer

  2013cites this paper
• Interaction between docetaxel resistance and castration resistance in prostate cancer: Implications of twist1, YB‐1, and androgen receptor

  2013cites this paper
• Therapie des kastrationsrefraktären Prostatakarzinoms

  2012cites this paper
• Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

  2012cites this paper
• Management of biochemical recurrence after localized treatment for prostate cancer

  2012cites this paper
• [Therapy of castration-resistant prostate cancer].

  2012cites this paper
• Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation

  2011cites this paper
• Is there a role for chemotherapy in nonmetastatic prostate cancer?

  2010cites this paper
• Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer

  2010cites this paper
• Does chemotherapy have a role before hormone-resistant disease develops?

  2009cites this paper
• A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.

  2009cites this paper
• Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts

  2008cites this paper
• Prostate cancer. Multidisciplinary approach: a key to success.

  2008cites this paper
• Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

  2008cites this paper
• Chemotherapie beim Prostatakarzinom

  2008cites this paper
• Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.

  2007cites this paper
• The medical management of prostate cancer: a multidisciplinary team approach

  2007cites this paper
• Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.

  2007cites this paper
• Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer

  2007cites this paper
• VIA.2 Prostate cancer – Multidisciplinary approach: a key to success

  2007cites this paper
• Effect of Calcitriol on Prostate-Specific Antigen In vitro and in Humans

  2006cites this paper
• Changing perspectives of the role of chemotherapy in advanced prostate cancer.

  2006cites this paper
• Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

  2006cites this paper
• Pre-clinical toxicology and pathology of 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), a novel anti-cancer agent in male Beagle dogs.

  2006cites this paper
• Docetaxel for the treatment of prostate cancer.

  2005cites this paper
• Docetaxel-based therapy for prostate cancer

  2005cites this paper
• What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer?

  2005cites this paper